ZA200507874B - P38 inhibitors and methods of use thereof - Google Patents

P38 inhibitors and methods of use thereof

Info

Publication number
ZA200507874B
ZA200507874B ZA200507874A ZA200507874A ZA200507874B ZA 200507874 B ZA200507874 B ZA 200507874B ZA 200507874 A ZA200507874 A ZA 200507874A ZA 200507874 A ZA200507874 A ZA 200507874A ZA 200507874 B ZA200507874 B ZA 200507874B
Authority
ZA
South Africa
Prior art keywords
inhibitors
methods
Prior art date
Application number
ZA200507874A
Other languages
English (en)
Inventor
Munson Mark
David A Mareska
Kim Youngboo
Groneberg Robert
Rizzi James
Rodriguez Martha
Kim Ganghyeok
Vigers Guy
Rao Chang
Balachari Devan
Harvey Darren
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ZA200507874B publication Critical patent/ZA200507874B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200507874A 2003-03-03 2004-02-25 P38 inhibitors and methods of use thereof ZA200507874B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/378,164 US7135575B2 (en) 2003-03-03 2003-03-03 P38 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
ZA200507874B true ZA200507874B (en) 2007-03-28

Family

ID=32926418

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200507874A ZA200507874B (en) 2003-03-03 2004-02-25 P38 inhibitors and methods of use thereof

Country Status (29)

Country Link
US (5) US7135575B2 (de)
EP (4) EP1997810B1 (de)
JP (2) JP5424657B2 (de)
KR (3) KR101236608B1 (de)
CN (2) CN101759645B (de)
AR (2) AR043451A1 (de)
AT (1) ATE410421T1 (de)
AU (1) AU2009225343B2 (de)
BR (2) BRPI0407993B8 (de)
CL (2) CL2004000416A1 (de)
CO (1) CO5670351A2 (de)
CY (4) CY1108661T1 (de)
DE (1) DE602004016970D1 (de)
DK (5) DK1997811T3 (de)
DO (1) DOP2009000155A (de)
EG (1) EG27049A (de)
ES (4) ES2315641T3 (de)
HK (2) HK1084673A1 (de)
IL (3) IL170527A (de)
IS (1) IS2959B (de)
NO (1) NO20085373L (de)
NZ (3) NZ572694A (de)
PA (1) PA8596901A1 (de)
PL (1) PL219742B1 (de)
PT (4) PT1997811E (de)
SI (5) SI1997811T1 (de)
TW (2) TWI346663B (de)
UA (2) UA103873C2 (de)
ZA (1) ZA200507874B (de)

Families Citing this family (357)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
EP1663237B1 (de) * 2003-09-10 2013-06-19 Icagen, Inc. Kondensierte ringheterozyklen als kaliumkanalmodulatoren
KR20060101488A (ko) * 2003-10-17 2006-09-25 인사이트 코포레이션 매트릭스 메탈로프로테이나제의 억제제로서의 치환된시클릭 히드록사메이트
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
KR101164258B1 (ko) 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005085206A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
AU2005219517A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CA2557575A1 (en) * 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
PL1778686T3 (pl) * 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
EP1647549A1 (de) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazole, Benzisoxazole und Benzisothiazole mit oestrogenen Eigenschaften
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1851200B1 (de) 2005-02-25 2014-01-15 Tetralogic Pharmaceuticals Corporation Dimere iap-hemmer
US7683045B2 (en) * 2005-03-22 2010-03-23 Innate Pharma S.A. Class of γδ T cells activators and use thereof
US8362075B2 (en) * 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
US8343953B2 (en) * 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (de) * 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmazeutische kombinationen mit pyrazol-derivaten als proteinkinase-modulatoren
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006279810B2 (en) * 2005-08-11 2011-10-27 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2007023115A2 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
JP2009506007A (ja) * 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
PL1944290T3 (pl) * 2005-09-14 2014-07-31 Ayumi Pharmaceutical Corp Nowa pochodna 1-2-dihydrochinoliny mająca aktywność wiązania glukokortykoidowego receptora
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20100022571A1 (en) * 2005-09-16 2010-01-28 Palle Venkata P Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
NZ567570A (en) * 2005-10-12 2011-02-25 Vertex Pharma Biphenyl derivatives as modulators of voltage gated ion channels
WO2007047397A2 (en) * 2005-10-13 2007-04-26 Smithkline Beecham Corporation Phenol ethers as modulators of the opioid receptors
PT2090575E (pt) 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2007087068A2 (en) * 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
RU2442777C2 (ru) * 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010503654A (ja) * 2006-09-12 2010-02-04 ファイザー・プロダクツ・インク ベンゾイミダゾロン誘導体
JP5714228B2 (ja) 2006-09-25 2015-05-07 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
EP2085387B1 (de) 2006-11-14 2013-04-10 Santen Pharmaceutical Co., Ltd Neues 1,2-dihydrochinolinderivat mit substituierter phenylchalcogenoniederalkylgruppe und über einen ester eingeführter phenylgruppe als substituenten
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
MX2009007670A (es) * 2007-01-18 2011-11-18 Evolva Sa 1,3-dioxanos sustituidos utiles como moduladores de paar.
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
EP2126574B1 (de) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondriale aldehyd-dehydrogenase-2-modulatoren und verwendungsverfahren dafür
US8030344B2 (en) * 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
MX2009010243A (es) * 2007-03-23 2009-12-14 Abbott Gmbh & Co Kg Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
WO2008118991A1 (en) * 2007-03-26 2008-10-02 University Of Southern California Usc Stevens Methods and compositions for inducing apoptosis by stimulating er stress
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
EP2011786A1 (de) * 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indanamin-Derivate, ihre Herstellung und Verwendung als Arzneimittel
DE102007032347A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
WO2009015000A1 (en) * 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US8227492B2 (en) * 2007-08-07 2012-07-24 Cadila Healthcare Limited Sulfoxamine derivatives as factor Xa inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) * 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
FR2924712B1 (fr) * 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
AU2009217543A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
EP2265609B1 (de) * 2008-02-29 2012-09-05 Array Biopharma, Inc. Als raf-inhibitoren verwendete imidazo[4,5-b]pyridinderivate
PL2105164T3 (pl) * 2008-03-25 2011-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści P2X7R i ich zastosowanie
US20090246234A1 (en) * 2008-04-01 2009-10-01 Benjamin Johnson Therapeutic Treatment Using Niacin for Skin Disorders
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
WO2009144009A1 (en) * 2008-05-26 2009-12-03 Medizinische Universität Innsbruck Medical intervention in haematological cancers
EP2730580A1 (de) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronatesterverbindungen und pharmazeutische Zusammensetzungen davon
JP5504158B2 (ja) * 2008-06-25 2014-05-28 学校法人慶應義塾 医薬組成物
EP2313372B1 (de) * 2008-08-06 2013-04-10 Vertex Pharmaceuticals Incorporated Aminopyridine als kinaseinhibitoren
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102149407A (zh) * 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
KR100905419B1 (ko) * 2008-09-11 2009-07-02 연세대학교 산학협력단 세스퀴테르펜 유도체의 용도
BRPI0920533A2 (pt) * 2008-10-01 2020-12-15 Novartis Ag Antagonismo de estabilizado para o tratamento de distúrbios relacionados à trilha de porco-espinho
US8653143B2 (en) * 2008-10-09 2014-02-18 Newtree Co., Ltd. Use of panduratin derivative or Boesenbergia pandurata extract
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8389522B2 (en) * 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
DE102008059133A1 (de) * 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
KR20100060189A (ko) * 2008-11-27 2010-06-07 국립암센터 에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) * 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
ES2628233T3 (es) * 2009-01-12 2017-08-02 Biokier Inc. Composición y método para el tratamiento de la diabetes
WO2010081488A1 (en) * 2009-01-15 2010-07-22 Humanitas Mirasole S.P.A. Nitric oxide furoxan derivative compounds endowed with antitumoral activity
EP2389362B1 (de) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylaminderivate und deren medizinische verwendung
US20100204329A1 (en) * 2009-02-06 2010-08-12 Mcfaul William J Method of using and establishing an absorption rate level and a neuron firing level
US20120046364A1 (en) * 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
JP5745505B2 (ja) * 2009-05-07 2015-07-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換フェニル尿素および置換フェニルアミド
EP2429291B1 (de) 2009-05-13 2016-07-06 Cydex Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen mit prasugrel- und cyclodextrinderivaten sowie verfahren zu ihrer herstellung und verwendung
EP2440205B1 (de) 2009-06-12 2014-08-27 United Therapeutics Corporation Iminozucker zur verwendung in der behandlung von bunyaviralen und togaviralen erkrankungen
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
CN102066372B (zh) * 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives
EP2480551A1 (de) * 2009-09-23 2012-08-01 Pfizer Inc. Gpr-119-modulatoren
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
EP2504002B1 (de) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
US8563610B2 (en) * 2010-02-04 2013-10-22 Rutgers, The State of New Jersey Polyunsaturated fatty acids interactions and oxidative stress disorders
RU2012139491A (ru) 2010-02-11 2014-03-20 Вандербилт Юниверсити Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
ES2727273T3 (es) 2010-03-08 2019-10-15 Spectrum Pharmaceuticals Inc Terapias inhibidoras de la autofagia basadas en tioxantina para tratar el cáncer
EP3133059A1 (de) * 2010-04-19 2017-02-22 Oryzon Genomics, S.A. Lysinspezifische demethylase-1-hemmer und deren verwendung
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US20130035332A1 (en) * 2010-04-29 2013-02-07 Layton Mark E Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
GB201008005D0 (en) * 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP3354635A1 (de) * 2010-05-14 2018-08-01 Agency For Science, Technology And Research Neuartige antimikrobielle verbindungen und verwendungen davon
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
MX337106B (es) * 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
GB201010359D0 (en) * 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
TW201204733A (en) * 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
US8846671B2 (en) * 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
JP2013530250A (ja) * 2010-07-13 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 二環式ピリミジン化合物
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
SI2599774T1 (sl) * 2010-07-29 2017-03-31 Astellas Pharma Inc. Zgoščene piridinske spojine kot CB2 kanabinoidni receptorski ligandi
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
PL392436A1 (pl) * 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
US8829026B2 (en) * 2010-10-01 2014-09-09 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
NZ610331A (en) * 2010-10-20 2015-01-30 Biota Scient Management Viral polymerase inhibitors
TWI537258B (zh) * 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
BR112013012488B1 (pt) * 2010-11-24 2021-08-31 Merck Patent Gmbh Azetidinas quinazolina carboxamida, seus usos e seu processo de fabricação, composição farmacêutica, e kit
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012075242A2 (en) * 2010-12-01 2012-06-07 Washington State University Research Foundation Controlled chemical release of hydrogen sulfide
EA039943B1 (ru) 2011-01-07 2022-03-30 Анджи Фарма (Юс) Элэлси Способ снижения уровней глюкозы в крови у субъекта
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
ES2610362T3 (es) * 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
EP3981395A1 (de) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
US20120208872A1 (en) * 2011-02-11 2012-08-16 Taipei Medical University Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
PE20140859A1 (es) * 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
US8642655B2 (en) * 2011-03-09 2014-02-04 Benjamin Johnson Systems and methods for preventing cancer and treating skin lesions
WO2012129074A1 (en) * 2011-03-18 2012-09-27 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2012127466A1 (en) * 2011-03-24 2012-09-27 Bar Ilan University 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
WO2012142474A2 (en) 2011-04-13 2012-10-18 Thermolife International, Llc N-acetyl beta alanine methods of use
ES2617215T3 (es) * 2011-04-19 2017-06-15 Daiichi Sankyo Company, Limited Derivado de tetrahirotiazepina
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2524694A1 (de) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
US8487008B2 (en) * 2011-06-22 2013-07-16 Universita Degli Studi Di Padova Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US8658677B2 (en) * 2011-07-07 2014-02-25 Aria Neurosciences Inc. Pyridyl-2-methylamino compounds, compositions and uses thereof
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
WO2013018929A1 (en) * 2011-08-04 2013-02-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
EP2744775B1 (de) * 2011-08-19 2018-03-07 Emory University Bax-agonist, zusammensetzungen und zugehörige verfahren
EP3473099A1 (de) 2011-09-14 2019-04-24 Samumed, LLC Indazol-3-carboxamide und deren verwendung als wnt/b-catenin-signalisierungsweghemmer
AR087841A1 (es) * 2011-09-14 2014-04-23 Chiesi Farma Spa Derivados de tetrahidrotriazolopirimidina
BR112014006927A2 (pt) * 2011-09-26 2017-04-04 Gruenenthal Gmbh derivados de metanossulfonamida substituídos com amina como ligantes de receptor vaniloide
EP2760835A1 (de) 2011-09-26 2014-08-06 Grünenthal GmbH Aryl- oder n-heteroaryl-substituierte methansulfonamidderivate als vanilloidrezeptorliganden
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
AU2012328837B2 (en) 2011-10-26 2015-07-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EP2780316B1 (de) * 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Ester von dcpla und behandlungsverfahren damit
AU2012340887A1 (en) 2011-11-22 2014-07-03 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
CA2857109A1 (en) * 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
EP2800562A2 (de) 2012-01-06 2014-11-12 Elcelyx Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
CN102603493B (zh) * 2012-01-17 2014-03-12 青岛农业大学 含氟邻烯丙基苯酚类化合物的制备方法及农用生物活性
WO2013123218A1 (en) * 2012-02-14 2013-08-22 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
CN102614177B (zh) * 2012-03-06 2014-08-06 北京伟峰益民科技有限公司 卢帕他定在制备治疗慢性阻塞性肺病药物组合物中的应用
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2830613B1 (de) * 2012-03-30 2016-04-27 Nestec S.A. 4-oxo-2-pentaensäure und kardiovaskuläre gesundheit
US9499484B2 (en) * 2012-04-02 2016-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8835494B2 (en) * 2012-04-04 2014-09-16 Chiesi Farmaceutici S.P.A. Derivatives of 1-(2-halo-biphenyl-4-yl)-Alkanecarboxylic for the treatment of neurodegenerative diseases
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP2015520239A (ja) * 2012-06-20 2015-07-16 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５受容体のアロステリック調節剤としての置換二環式アルコキシピラゾール類似体
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CA2879431A1 (en) 2012-07-17 2014-01-23 Washington University Anti-mucus drugs and uses therefor
EP2882496B1 (de) * 2012-08-13 2019-10-09 The Rockefeller University Behandlung und diagnose von melanomen
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
AU2013307688A1 (en) * 2012-08-29 2015-04-09 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
US8859598B2 (en) * 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
US9278081B2 (en) * 2012-10-04 2016-03-08 University Of The West Indies Extracts from Eucalyptus camaldulensis for the treatment of hyperglycemia and hypertension
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9657024B2 (en) 2012-11-21 2017-05-23 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
EP2928879B1 (de) * 2012-12-05 2018-02-28 Chiesi Farmaceutici S.p.A. Phenylethylpyridin derivate als pde4-inhibitoren und muscarin rezeptor antagonisten
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
CA2897400A1 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
US9776972B2 (en) 2013-03-14 2017-10-03 Epizyme Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
EA030481B1 (ru) 2013-03-14 2018-08-31 Эпизим, Инк. Ингибиторы аргининметилтрансферазы и их применения
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (de) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazolderivate als prmt1-inhibitoren und verwendungen davon
US9611259B2 (en) 2013-03-15 2017-04-04 Janssen Pharmaceutica Nv Substituted pyridine derivatives useful as C-FMS kinase inhibitors
US20140335079A1 (en) * 2013-05-07 2014-11-13 Emory University Solenopsin and derivatives, therapeutic compositions, and methods related thereto
DK3017814T3 (en) * 2013-07-03 2018-03-12 Mitsubishi Chemical Foods Corp PROCEDURE FOR PREVENTION AND / OR TREATMENT OF DIGITAL DERMATITIS
BR112016000779A8 (pt) 2013-07-18 2020-01-07 Novartis Ag inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas
US20150045435A1 (en) * 2013-08-06 2015-02-12 Indiana University Research And Technology Corporation Compounds and methods for treating diabetes
WO2015026574A1 (en) * 2013-08-20 2015-02-26 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
WO2015027160A2 (en) * 2013-08-22 2015-02-26 Northeastern University Allosteric modulators of the cannibinoid 1 receptor
JP2016530333A (ja) 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
EP3052190A4 (de) * 2013-10-01 2017-07-19 New York University Amino-, amido- und heterocyclische verbindungen als modulatoren der wutaktivität und verwendungen davon
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
KR20160096612A (ko) * 2013-12-13 2016-08-16 다이이찌 산쿄 가부시키가이샤 5-하이드록시-4-(트리플루오로메틸)피라졸로피리딘 유도체
EP3082782A1 (de) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Kombinationen aus serotonin-norepinephrin-wiederaufnahmehemmern (snris) und sigma-rezeptorliganden
US9381171B2 (en) * 2013-12-19 2016-07-05 Samsung Electronics Co., Ltd. Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition
WO2015091934A1 (en) * 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-azetidinyl substituent and use thereof for treating vasopressine-related diseases
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3091970B1 (de) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr-agonisten und verwendungen davon
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2017508810A (ja) 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト シアノ置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
EP3145526A1 (de) 2014-05-20 2017-03-29 Millennium Pharmaceuticals, Inc. Borhaltige proteasom-hemmer zur verwendung nach der primären krebstherapie
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
EP3222278B1 (de) * 2014-10-24 2023-06-14 Launx Biomedical Co., Ltd. Verwendung von azelnidipin zur herstellung einer medizinischen zusammensetzung zur behandlung von krebs
EP3215140A4 (de) * 2014-11-06 2018-05-02 The Arizona Board of Regents On Behalf of the University of Arizona Zusammensetzungen und verfahren für prodrugs auf diazeniumdiolatbasis zur behandlung von krebs
WO2016073983A2 (en) * 2014-11-07 2016-05-12 Northwestern University Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
BR112017011764A2 (pt) * 2014-12-02 2018-07-10 Kempharm, Inc. ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de oximorfona, pro-fármacos, métodos e preparação e uso dos mesmos
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
US10507210B2 (en) * 2014-12-03 2019-12-17 Auckland Uniservices Limited Kinase inhibitor prodrug for the treatment of cancer
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
US9763896B2 (en) 2015-01-22 2017-09-19 Mitochon Pharmaceuticals, Inc. Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
DK3265087T3 (da) 2015-03-04 2020-10-19 Vanda Pharmaceuticals Inc Fremgangsmåde til behandling med tradipitant
CA2980730A1 (en) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
JP2018513865A (ja) * 2015-04-20 2018-05-31 エピザイム，インコーポレイティド 癌を処置するための併用療法
CA2982824C (en) * 2015-04-30 2023-11-21 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
TWI713534B (zh) 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US9675608B2 (en) * 2015-08-26 2017-06-13 Macau University Of Science And Technology Identification of natural small-molecules AMPK activators for treatment of cancers or multidrug-resistant cancers
KR20180061363A (ko) * 2015-10-08 2018-06-07 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Wnt 신호 전달 경로 억제제 및 이의 치료적 적용
GB201519450D0 (en) * 2015-11-03 2015-12-16 Univ Liverpool Novel treatment
CA3004506A1 (en) 2015-11-06 2017-05-11 Samumed, Llc Use of n-(5-(3-(7-(3- fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide in the treatment of osteoarthritis
US9549907B1 (en) * 2015-11-13 2017-01-24 Sovereign Pharmaceuticals, Llc Immediate release oral guaifenesin solution
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN109641886B (zh) * 2015-11-25 2022-11-18 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
WO2017153459A1 (en) * 2016-03-09 2017-09-14 Netherlands Translational Research Center B.V. Inhibitors of indoleamine 2,3-dioxygenase
WO2017160703A1 (en) * 2016-03-14 2017-09-21 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
US10064834B2 (en) * 2016-05-09 2018-09-04 Texas Tech University System Carbidopa for the treatment of cancer
WO2017197036A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017201712A1 (zh) * 2016-05-26 2017-11-30 中国热带农业科学院热带生物技术研究所 诺卡酮的应用
CA3026076A1 (en) 2016-06-01 2017-12-07 Samumed, Llc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
EP3251668A1 (de) * 2016-06-02 2017-12-06 Pharmotech SA Cannabidiolzusammensetzungen und verwendungen davon
EP4233840A3 (de) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin
AU2017324510B2 (en) 2016-09-07 2023-08-31 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
EP3446704A1 (de) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf eine effiziente folatalternative in 5-fluoruracilbasierter chemotherapie
EP3446703A1 (de) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf-mehrfachbolusverabreichung in 5-fluoruracil-basierter chemotherapie
WO2018075858A1 (en) 2016-10-21 2018-04-26 Samumed, Llc Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
JP2019533702A (ja) 2016-11-07 2019-11-21 サミュメッド リミテッド ライアビリティ カンパニー 単回用量の調整済み注射用製剤
EP3541395A4 (de) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. Verfahren zur behandlung einer glykogenspeicherkrankheit
EP3554263B1 (de) * 2016-12-15 2023-07-19 Société des Produits Nestlé S.A. Zusammensetzungen und verfahren zur modulierung der verdaulichkeit bei einem haustier
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
WO2018138028A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
WO2018138029A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3573969A1 (de) 2017-01-26 2019-12-04 Boehringer Ingelheim International GmbH Benzyloxypyrazinylcyclopropancarbonsäuren, pharmazeutische zusammensetzungen und verwendungen davon
EP3580222B1 (de) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylessigsäuren, pharmazeutische zusammensetzungen zur behandlung von diabetes
NZ756408A (en) 2017-02-14 2024-01-26 Isofol Medical Ab Methods for increasing blood plasma 2’-deoxyuridine (durd) and thymidylate synthase inhibition
US10517842B2 (en) * 2017-03-15 2019-12-31 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods of modulating miRNA levels and compositions for use in the same
RU2675496C1 (ru) * 2017-03-31 2018-12-20 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения алкиловых эфиров гидроксибензойных кислот
KR102342620B1 (ko) 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
US20180280319A1 (en) * 2017-04-04 2018-10-04 University Of The Sciences Compounds and compositions for treatment of breast cancer
FR3066393B1 (fr) * 2017-05-16 2019-07-19 Polyneuros Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CA3069339A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
US10639313B2 (en) * 2017-09-01 2020-05-05 Ndsu Research Foundation Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
WO2019084323A1 (en) * 2017-10-25 2019-05-02 Georgia State University Research Foundation, Inc. CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT
MX2020004946A (es) 2017-11-03 2020-09-25 Aclaris Therapeutics Inc Inhibidores jak de pirrolopiridina sustituidos y metodos para producir y utilizar los mismos.
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
JP7196201B2 (ja) 2018-06-04 2022-12-26 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
JP2021534244A (ja) 2018-08-10 2021-12-09 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
CA3099776A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
KR20220004726A (ko) 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Jak 억제제로서의 치환된 피롤로피리딘
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
AU2021409656A1 (en) 2020-12-21 2023-07-06 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
CN113354558B (zh) * 2021-07-12 2022-03-11 无锡双启科技有限公司 一种2-氨基-5-氟苯腈的制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS5998060A (ja) * 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
US5234942A (en) 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
SU1545940A3 (ru) 1984-10-19 1990-02-23 Ай-Си-Ай Америказ Инк (Фирма) Способ получени гетероциклических кислот или их солей
PL265549A1 (en) 1985-03-26 1988-09-01 The method of manufacture of new heterocyclic amides
JPS6368568A (ja) * 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
IL97102A0 (en) 1990-02-16 1992-03-29 Ici Plc Heterocyclic compounds
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5616537A (en) 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
EP0684235A1 (de) 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Azolyl-methyl-phenyl Derivate mit Aromatase inhibierender Aktivität
JPH0841032A (ja) * 1994-05-27 1996-02-13 Mochida Pharmaceut Co Ltd アロマターゼ阻害作用を有する新規なアゾールメチルフェニル誘導体
AU702146B2 (en) 1995-10-06 1999-02-11 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL128642A0 (en) 1996-09-04 2000-01-31 Pfizer Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US5932570A (en) 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6218386B1 (en) 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
CA2270966A1 (en) 1996-11-08 1998-05-14 Du Pont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
PL191111B1 (pl) 1997-04-24 2006-03-31 Ortho Mcneil Pharm Inc Podstawione imidazole, sposób ich wytwarzania, kompozycje zawierające podstawione imidazole oraz ich zastosowanie
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
NZ503685A (en) 1997-10-20 2002-05-31 F Fused pyrrole compounds as kinase inhibitors
AU1367599A (en) 1997-11-03 1999-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
HUP0100330A3 (en) 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
US6329412B1 (en) * 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
AU2566399A (en) 1998-02-12 1999-08-30 University Of Delaware Catalyst compounds with beta-diiminate anionic ligands and processes for polymerizing olefins
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EE04799B1 (et) 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
NZ529882A (en) 1999-03-29 2005-05-27 Shire Biochem Inc Methods of treating leukemia
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
CN100408576C (zh) 1999-04-21 2008-08-06 惠氏控股有限公司 取代的3-氰基-[1.7],[1.5]和[1.8]-二氮杂萘酪氨酸激酶抑制剂
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
ATE376547T1 (de) 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
WO2001004115A2 (en) * 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
JP4234858B2 (ja) 1999-09-21 2009-03-04 東芝テック株式会社 負極性現像剤
EP1235806A4 (de) * 1999-11-27 2004-02-04 Dong Wha Pharm Ind Co Ltd Neue 5-pyrimidincarboxamid-derivate und diese derivate enthaltende pharmazeutische gemische
EP1235804A1 (de) * 1999-11-27 2002-09-04 Dong Wha Pharmaceutical Industrial Co. Ltd. Neue 3-nitropyridin-derivate und diese derivate enthaltende pharmazeutische gemische
JP2003523952A (ja) 1999-11-27 2003-08-12 ドン ファ ファーマシューティカル インダストリアル カンパニー リミテッド 新規な３−ニトロピリジン誘導体及び該誘導体を含む製薬組成物
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
AU2002226911A1 (en) 2000-11-20 2002-06-03 Scios Inc. Indol derivative and their use as inhibitors of p38 kinase
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
PL363959A1 (en) 2001-03-09 2004-11-29 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
KR20040047869A (ko) 2001-09-26 2004-06-05 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
EP1438048A1 (de) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituierte benzokondensierte harnstoffverbindungen als cytokinhemmer
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003087072A1 (fr) 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a des troubles endotheliaux
ATE421505T1 (de) 2002-07-19 2009-02-15 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
BR0314098A (pt) * 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm
RU2005115842A (ru) 2002-10-24 2006-03-10 Мерк Патент ГмбХ (DE) Производные метиленмочевины
EP1562935B1 (de) 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004052280A2 (en) 2002-12-10 2004-06-24 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
JP2007514791A (ja) 2003-12-18 2007-06-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐ３８ｍａｐキナーゼインヒビターであるｂｉｒｂ７９６の多形
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
US20060264431A1 (en) 2005-05-11 2006-11-23 Array Biopharma Inc. P38 inhibitors and methods of use thereof
RU2442777C2 (ru) 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения

Also Published As

Publication number Publication date
TWI343386B (en) 2011-06-11
CN1784396A (zh) 2006-06-07
KR20090021231A (ko) 2009-02-27
ATE410421T1 (de) 2008-10-15
SI1997810T1 (sl) 2013-12-31
CL2009000234A1 (es) 2009-04-24
PT1606283E (pt) 2008-12-29
KR20120037022A (ko) 2012-04-18
ES2534859T3 (es) 2015-04-29
TW200510416A (en) 2005-03-16
US20040180896A1 (en) 2004-09-16
CY1115441T1 (el) 2017-01-04
DK1606283T3 (da) 2009-02-09
EP1997809A2 (de) 2008-12-03
EP2039685A3 (de) 2009-12-02
US8017641B2 (en) 2011-09-13
KR20110091532A (ko) 2011-08-11
DOP2009000155A (es) 2010-09-15
AR069413A2 (es) 2010-01-20
JP5687259B2 (ja) 2015-03-18
EP1997810B1 (de) 2013-07-31
ES2484866T3 (es) 2014-08-12
NO20085373L (no) 2005-11-29
EP2039685A2 (de) 2009-03-25
PT1997811E (pt) 2015-07-29
PT1997810E (pt) 2013-11-07
EP1997809B1 (de) 2014-05-14
SI2039685T1 (sl) 2013-04-30
CN100579976C (zh) 2010-01-13
CO5670351A2 (es) 2006-08-31
ES2433096T3 (es) 2013-12-09
CY1114554T1 (el) 2016-10-05
US20040176325A1 (en) 2004-09-09
US20090143422A1 (en) 2009-06-04
US8518983B2 (en) 2013-08-27
IL196847A0 (en) 2011-07-31
IL215917A0 (en) 2011-12-29
BRPI0419305B8 (pt) 2021-05-25
PL219742B1 (pl) 2015-07-31
JP2012251003A (ja) 2012-12-20
HK1084673A1 (en) 2006-08-04
PL400577A1 (pl) 2013-02-18
SI1997809T1 (sl) 2014-09-30
PA8596901A1 (es) 2004-11-26
CN101759645A (zh) 2010-06-30
AU2009225343A1 (en) 2009-11-05
DK1997809T3 (da) 2014-07-21
NZ542616A (en) 2009-02-28
EP1997811A3 (de) 2009-09-09
EP1997809A3 (de) 2009-09-09
BRPI0419305B1 (pt) 2019-10-22
IL170527A (en) 2011-11-30
SI1997811T1 (sl) 2015-07-31
CN101759645B (zh) 2014-06-25
TW200936590A (en) 2009-09-01
IS8810A (is) 2009-03-16
US7799782B2 (en) 2010-09-21
DK1997811T3 (en) 2015-07-06
KR101236608B1 (ko) 2013-02-22
EP2039685B1 (de) 2012-12-26
UA86196C2 (uk) 2009-04-10
BRPI0407993B1 (pt) 2018-05-22
PT1997809E (pt) 2014-08-26
DK1997810T3 (da) 2013-10-21
EP1997810A2 (de) 2008-12-03
EP1997811A2 (de) 2008-12-03
SI1606283T1 (sl) 2009-04-30
CL2004000416A1 (es) 2005-01-14
NZ582796A (en) 2011-05-27
UA103873C2 (ru) 2013-12-10
EP1997811B1 (de) 2015-04-08
DK2039685T3 (da) 2013-03-25
BRPI0407993B8 (pt) 2021-05-25
HK1146664A1 (zh) 2011-06-30
JP2009102395A (ja) 2009-05-14
DE602004016970D1 (de) 2008-11-20
AR043451A1 (es) 2005-07-27
IS2959B (is) 2017-02-15
CY1108661T1 (el) 2014-04-09
US7135575B2 (en) 2006-11-14
US20090149459A1 (en) 2009-06-11
US20090136596A1 (en) 2009-05-28
EG27049A (en) 2015-04-28
NZ572694A (en) 2010-04-30
JP5424657B2 (ja) 2014-02-26
TWI346663B (en) 2011-08-11
AU2009225343B2 (en) 2012-08-23
EP1997810A3 (de) 2009-12-02
ES2315641T3 (es) 2009-04-01
CY1116207T1 (el) 2017-02-08
BRPI0407993A (pt) 2006-03-07

Similar Documents

Publication Publication Date Title
TWI346663B (en) P38 inhibitors and methods of use thereof
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
AU2003303128A8 (en) Inhibitors and methods of use thereof
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
EP1606285A4 (de) Neue ido-hemmer und anwendungsverfahren
EP1507756A4 (de) Ccr9-inhibitoren und verfahren zu deren verwendung
EP1465615A4 (de) Trizyklische bisenon-derivate und verfahren zu ihrer verwendung
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
AU2003259735A8 (en) Small-mer compositions and methods of use
EP1691812A4 (de) Gtpase-hemmer und anwendungsverfahren
EP1448218A4 (de) Beta-secretase-hemmer und anwendungsverfahren
EP1639086A4 (de) Rna-interferasen und verfahren zur verwendung davon
ZA200601293B (en) Proteasome inhibitors and methods of using the same
EP1789437A4 (de) Npc1l1 und npc1l1-inhibitoren und verfahren zu deren anwendung
EP1476150A4 (de) Carboxyfullerene und verwendungsverfahren dafür
AU2003299441A8 (en) Nf-hev compositions and methods of use
EP1663255A4 (de) Withanamid und withanolid-zusammensetzungen und anwendungsverfahren dafür
EP1633749A4 (de) Deazaflavinverbindungen und verfahren zu deren anwendung
EP1883404A4 (de) P38-hemmer und anwendungsverfahren dafür
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1682115A4 (de) Hif-1-hemmer und anwendungsverfahren dafür